RESUMO
This study aimed to compare the minimum anesthetic concentration (MAC) of sevoflurane in green iguanas using elec- trical stimulation and tail clamping as noxious stimuli. Seven adult green iguanas (Iguana iguana) weighing 580 to 1,300 g were enrolled. Each iguana was anesthetized twice after a 1-week washout period, with MAC being determined using a tail clamp (MACt) or electrical stimulation (MACe ) techniques. After sevoflurane mask induction and endotracheal intubation, the fraction of expired sevoflurane (Fe 'Sevo) was maintained at 3.1% for 15 min before noxious stimulation. In a bracketing design, the subsequent Fe'Sevo values were increased or decreased by 10% after positive or negative responses, respectively. Each targeted Fe 'Sevo was kept constant for 15 min before stimulation. In MACt, the noxious stimulus involved closing a Kelly hemostatic curved forceps to the first ratchet at the base of the tail. At the same site, in MACe, 2 30 × 0.8-mm hypodermic needles inserted 1 cm apart were connected to an electrical stimulator set to deliver 30 mA at 50 Hz at a 6.5-ms interval. The hemostat and the needles were repositioned 2 cm distally and on alternate tail sides at each stimulation round. Individual MAC was obtained when 2 consecutive crossover events occurred (a positive response preceding a negative response or vice versa), with the MAC of each group represented by the average of the individual MAC values. Median (interquartile range) values for the sevoflurane MAC did not differ significantly between groups (2.2 [2.2 to 2.8%] in MACe and 2.2 [1.8 to 3.5%] in MACt ; P = 0.812). Time to anesthesia induction, time to MAC measurement, heart rate (HR), end-tidal carbon dioxide (ET'CO2), and cloacal temperature were not different between groups. Both the tail-clamping and the electrical stimulation techniques yielded resembling sevoflurane MAC values in green iguanas, which makes the tail clamp a reliable alternative to electrical stimulation-based MAC research in this species.
Assuntos
Anestésicos Inalatórios , Estimulação Elétrica , Iguanas , Sevoflurano , Cauda , Sevoflurano/farmacologia , Animais , Anestésicos Inalatórios/análise , Anestésicos Inalatórios/administração & dosagem , Estimulação Elétrica/métodos , Masculino , Feminino , Éteres Metílicos/análiseRESUMO
OBJECTIVES: This study aimed to assess the effect of dexmedetomidine on the propofol-based anesthesia of cats subjected to ovariohysterectomy. METHODS: Twenty-eight cats were randomly allocated to four groups (seven cats in each) and premedicated with either 5 µg/kg dexmedetomidine (groups Dex 1, Dex 3 and Dex 5) or 0.05 ml saline (Prop group) intramuscularly. After the induction of anesthesia with propofol, total intravenous anesthesia was initiated with 300 µg/kg/min propofol plus 3 ml/kg/h NaCl 0.9% (Prop), or 200 µg/kg/min propofol plus dexmedetomidine at the rates of 1 µg/kg/h (Dex 1), 3 µg/kg/h (Dex 3) or 5 µg/kg/h (Dex 5). Cardiorespiratory variables were assessed 5 mins after induction and every 10 mins thereafter, until the end of anesthesia. The propofol infusion rate was adjusted every 10 mins (± 50 µg/kg/min) to maintain anesthetic depth. The times to extubation, sternal recumbency, ambulation and total recovery were recorded. Pain scoring was performed 1, 2, 4, 8, 12 and 24 h after the end of anesthesia. RESULTS: Dexmedetomidine produced a propofol-sparing effect of 72.8%, 71.1% and 74.6% in the Dex 1, Dex 3 and Dex 5 groups, respectively. Cats in the Prop group maintained higher heart rate values than the other groups, and the mean arterial pressure remained higher in the Dex 3 and Dex 5 groups. Rescue intraoperative analgesia (fentanyl bolus) was most frequent in the Prop group. There was no significant difference in the time of extubation. Cats in the Dex 1 and Dex 3 groups had a faster anesthetic recovery, with shorter times to achieving sternal recumbency, regaining ambulation and reaching full recovery. Cats in the Dex 1 and Dex 5 groups presented the best recovery quality scores, with 4 (range 4-5) and 4 (range 3-5), respectively, while the Prop group scored 1 (range 1-3), the worst anesthetic recovery score among the groups. CONCLUSIONS AND RELEVANCE: The use of dexmedetomidine as a total intravenous anesthesia adjuvant, especially at doses of 1 and 3 µg/kg/h, reduces propofol consumption and improves cardiorespiratory stability and intraoperative analgesia, while promoting a better and quicker recovery from anesthesia.
Assuntos
Hipnóticos e Sedativos , Propofol , Animais , Gatos , Anestesia Intravenosa/veterinária , Propofol/administração & dosagem , Histerectomia , Ovariectomia , Hipnóticos e Sedativos/administração & dosagemRESUMO
Capybara (Hydrochoerus hydrochaeris) is the main host of tick-borne pathogens causing Brazilian spotted fever; therefore, controlling its population is essential, and this may require chemical restraint. We assessed the impact of chemical restraint protocols on the partial pressure of arterial oxygen (PaO2) and other blood variables in 36 capybaras and the effect of different flows of nasal oxygen (O2) supplementation. The capybaras were hand-injected with dexmedetomidine (5 µg/kg) and midazolam (0.1 mg/kg) and butorphanol (0.2 mg/kg) (DMB, n = 18) or methadone (0.1 mg/kg) (DMM, n = 18). One-third of the animals were maintained in ambient air throughout the procedure, and one-third were administered intranasal 2 L/min O2 after 30 min whereas the other third were administered 5 L/min O2. Arterial blood gases, acid-base status, and electrolytes were assessed 30 and 60 min after drug injection. The DMB and DMM groups did not vary based on any of the evaluated variables. All animals developed hypoxaemia (PaO2 44 [30; 73] mmHg, SaO2 81 [62; 93] %) 30 min before O2 supplementation. Intranasal O2 at 2 L/min improved PaO2 (63 [49; 97] mmHg and SaO2 [92 [85; 98] %), but 9 of 12 capybaras remained hypoxaemic. A higher O2 flow of 5 L/min was efficient in treating hypoxaemia (PaO2 188 [146; 414] mmHg, SaO2 100 [99; 100] %) in all the 12 animals that received it. Both drug protocols induced hypoxaemia, which could be treated with intranasal oxygen supplementation.